Compare CWCO & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | EOLS |
|---|---|---|
| Founded | 1973 | 2012 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 384.6M |
| IPO Year | 1997 | 2018 |
| Metric | CWCO | EOLS |
|---|---|---|
| Price | $32.23 | $8.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $40.00 | $15.50 |
| AVG Volume (30 Days) | 76.4K | ★ 932.4K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 0.48 | N/A |
| Revenue | $132,073,368.00 | ★ $297,176,000.00 |
| Revenue This Year | $4.34 | $13.27 |
| Revenue Next Year | $42.86 | $17.62 |
| P/E Ratio | $67.33 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $28.17 | $3.86 |
| 52 Week High | $39.12 | $8.43 |
| Indicator | CWCO | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 71.52 | 76.58 |
| Support Level | $31.73 | $5.84 |
| Resistance Level | $34.66 | N/A |
| Average True Range (ATR) | 0.75 | 0.37 |
| MACD | 0.23 | 0.24 |
| Stochastic Oscillator | 66.06 | 98.31 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.